Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M, Hu Y, Caillot D, Benboubker L, Zweegman S, Merz M, Weisel K, Salwender H, Mai EK, Goldschmidt H, Bertsch U, Vanquickelberghe V, Kampfenkel T, Boer C, Krotneva S, Proskorovsky I, He J, Lam A, Lee C, Cote S, Sonneveld P.
Moreau P, et al. Among authors: he j.
Immunotherapy. 2021 Feb;13(2):143-154. doi: 10.2217/imt-2020-0266. Epub 2020 Nov 24.
Immunotherapy. 2021.
PMID: 33228440